目的探讨缬沙坦治疗扩张型心肌病的疗效。方法回顾分析35例患者的临床资料。结果观察组17例中,显效13例,有效3例,无效1例,总有效率为89%;对照组18例中,显效11例,有效2例,无效5例,总有效率为71%。两组总有效率比较,差异有统计学意义(P<0.05)。见表2。不良反应:观察组部分患者出现恶心、疲劳、水肿、无力、头晕、腹痛、头痛、呼吸困难、心悸、消化不良,停药后症状缓解,未影响治疗。未发现肾功能不全及低血压和高血钾。结论本文表明缬沙坦治疗DCM疗效明显优于对照组(P<0.05),且副作用小,患者耐受性好,疗效确切,值得临床应用。 Objective To investigate the efficacy of valsartan in the treatment of dilated cardiomyopathy. Methods The clinical data of 35 patients were retrospectively analyzed. Results In the observation group of 17 cases, 13 cases were markedly effective, 3 cases were effective, 1 case was ineffective, and the total effective rate was 89%. In the control group, 11 cases were markedly effective, 2 cases were effective, 5 cases were ineffective and the total effective rate was 71% . The total effective rate between the two groups, the difference was statistically significant (P <0.05). See Table 2. Adverse reactions: Some patients in the observation group showed nausea, fatigue, edema, weakness, dizziness, abdominal pain, headache, dyspnea, heart palpitations, dyspepsia, relieved symptoms after stopping treatment and no effect on treatment. Renal insufficiency and hypotension and hyperkalemia were not found. Conclusion This article shows that valsartan in the treatment of DCM was significantly better than the control group (P <0.05), and the side effects of small, patients with good tolerance, effective, it is worth clinical application.